Abstract
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have